文献速递肿瘤 PET/CT甲状腺核医学核素与放射性配体治疗

68Ga-DOTATATE PET/CT与18F-FDG PET/CT在甲状腺乳头状癌TENIS综合征中的头对头比较:TSH升高与抑制状态下的初步研究

68 Ga-DOTATATE PET/CT Versus 18 F-FDG PET/CT in TENIS Syndrome: A Head-to-Head Comparison With Elevated and Suppressed TSH Levels in Papillary Thyroid Carcinoma-A Pilot Study.
PubMed 文献 · Clin Nucl Med · 2024-09-11

该前瞻性初步研究纳入15例TENIS综合征甲状腺乳头状癌患者,所有患者接受4次检查,在TSH升高(eTSH)和抑制(sTSH)两种条件下盲法比较68Ga-DOTATATE PET/CT与18F-FDG PET/CT的SUVmax及病灶检出率。SSR PET/CT在sTSH和eTSH条件下均较FDG PET/CT检出更多颈部及远处淋巴结转移,但TSH刺激未在患者层面增加FDG或DOTATATE PET的检出价值,且DOTATATE PET/CT在TSH刺激下特异性由84%降至74%。3例接受PRRNT的患者中1例出现视觉部分缓解。

要点

  • sTSH条件下SSR PET/CT较FDG PET/CT检出更多颈部淋巴结(P=0.0253和P=0.0176)及远处淋巴结(P=0.0253和P=0.0391)。
  • eTSH条件下SSR PET/CT较FDG PET/CT检出更多局部复发患者(P=0.0455)及远处淋巴结转移患者(P=0.0143)。
  • 两种示踪剂对肺和骨转移的检出无差异(κ=1),TSH刺激未在患者层面增加FDG或DOTATATE PET的检出价值(κ 0.6087–1)。

核心结论

  • TENIS综合征患者无论TSH水平如何,SSR PET/CT与FDG PET/CT整体准确率均较高(eTSH和sTSH下分别为86%–92%和92%–85%)。
  • SSR PET/CT在sTSH和eTSH条件下均较FDG PET/CT检出更多局部区域和远处淋巴结转移。
  • 3例接受PRRNT的患者中1例出现部分缓解。
  • 作者认为研究结果可能影响患者再分期、管理及放射性标记生长抑素类似物的诊疗一体化策略。

研究设计与样本

  • 前瞻性初步研究,纳入15例TENIS综合征甲状腺乳头状癌患者。
  • 所有患者接受4次检查,在TSH升高(eTSH)和抑制(sTSH)两种条件下行68Ga-DOTATATE PET/CT与18F-FDG PET/CT。
  • 参考标准包括颈部超声、CT、MRI、PET/CT、活检和随访。
  • 3例患者接受了PRRNT。

主要发现

  • sTSH条件下SSR PET/CT较sTSH FDG PET/CT在患者层面和病灶层面均检出更多颈部淋巴结(P=0.0253和P=0.0176)及远处淋巴结(P=0.0253和P=0.0391)。
  • eTSH条件下SSR PET/CT较eTSH FDG PET/CT检出更多局部复发患者(P=0.0455)及远处淋巴结转移患者(P=0.0143)。
  • 病灶层面分析显示eTSH条件下SSR PET/CT较eTSH FDG PET/CT检出更多颈部淋巴结(P=0.0337)及远处淋巴结(P=0.0039)。
  • 两种示踪剂对肺和骨远处转移的检出无差异(κ=1),常规CT部分亦检出所有骨和肺部病灶。
  • TSH刺激未在患者层面增加FDG或DOTATATE PET的检出价值(κ 0.6087–1),但DOTATATE PET/CT在TSH刺激下检出更多病灶,其中多数未被参考标准确认,导致特异性由84%降至74%。

关键数值与推荐

  • TENIS综合征定义为钠碘同向转运体表达降低、血清甲状腺球蛋白(Tg)升高及全身131I扫描阴性。
  • eTSH和sTSH条件下SSR PET/CT整体准确率分别为86%–92%和92%–85%,FDG PET/CT分别为92%–85%和86%–92%。
  • DOTATATE PET/CT在TSH刺激下特异性为74%,无TSH刺激时为84%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TENIS syndrome is characterized by reduced expression of sodium-iodine symporter, rising serum thyroglobulin (Tg) levels, and negative whole-body 131 I scans. In such patients, somatostatin receptor imaging with 68 Ga-DOTATATE PET/CT (somatostatin receptor [SSR] PET/CT) and 18 F-FDG PET/CT (FDG PET/CT) can identify metastases and were compared under 2 conditions: elevated (eTSH) and suppressed (sTSH) TSH serum levels. Potential candidates for peptide receptor radionuclide therapy (PRRNT) were identified in 15 patients prospectively enrolled. All patients underwent 4 examinations. Images were blindly evaluated for differences in SUV max values and lesion detectability. Reference standard consisted of neck ultrasound, CT, MRI, PET/CT, biopsy, and follow-up. Three patients were received PRRNT. RESULTS: sTSH SSR PET/CT detected a greater number of cervical ( P = 0.0253 and P = 0.0176) and distant LNs ( P = 0.0253 and P = 0.0391) when compared with sTSH FDG PET/CT, respectively, in a per-patient and on a per-lesion based analysis. Likewise, eTSH SSR PET/CT detected a greater number of patients with local recurrences ( P = 0.0455) and distant LN metastases ( P = 0.0143). Per-lesion analysis revealed greater number of cervical and distant LNs ( P = 0.0337 and P = 0.0039, respectively) when compared with eTSH FDG PET/CT. There was no difference in detection of distant metastases by both tracers for lung and bone metastases (κ = 1). Both skeletal and pulmonary lesions were also detected by conventional CT part of FDG or DOTATATE PET/CT scans. TSH stimulation had no additional value in a per-patient analysis for both FDG and DOTATATE PET scans (κ varying from 0.6087 to 1). However, TSH stimulation led to more lesion identifications in DOTATATE PET/CT; most of those metastases were not confirmed by the reference standard leading to a decrease in specificity (84% vs 74%). One of 3 patients submitted to 3 cycles of PRRNT presented with a visual partial response, a 20% reduction in quantitative analyses, and stable disease regarding Tg and TgAb levels. CONCLUSIONS: Patients with TENIS syndrome can be imaged with SSR PET/CT as well as FDG PET/CT with high overall accuracy regardless of TSH levels (86% to 92% and 92% to 85%, respectively, with eTSH and sTSH). SSR PET/CT detected a greater number of locoregional and distant LN metastases than FDG PET/CT with both sTSH and eTSH. One of 3 patients submitted to PRRNT presented a partial response to treatment. Our findings may impact in patient restaging, management, and theranostics strategies with radiolabeled somatostatin analogs.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Almeida LS, Santos A, Assumpção L, et al. 68 Ga-DOTATATE PET/CT Versus 18 F-FDG PET/CT in TENIS Syndrome: A Head-to-Head Comparison With Elevated and Suppressed TSH Levels in Papillary Thyroid Carcinoma-A Pilot Study. Clin Nucl Med. 2024. PMID: 39262048. doi:10.1097/RLU.0000000000005366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。